Healthier Future for Humanity with Genomic Technology.
BIONEER is the first Korean biotechnology company established in 1992. We had developed state-of-the-art molecular biology products and technologies including an oligonucleotide, thermostable polymerase, and instruments for gene manipulation such as automatic nucleic acid extractors, thermal cyclers, real-time qPCR instruments, and DNA sequencers. Since our incorporation, we have invested to integrate recombinant DNA technology, fermentation, biochemistry, nucleic acid chemistry, mechanics, photonics, and electronics. BIONEER has positioned to fully utilize its capability to develop next-generation technologies in the post-genome era through the invention of new biochemistry technologies and instruments. BIONEER currently runs a total of 226,000 square feet of two production facilities and research facilities.
Equipped with our patented 384 synthesizers, our facilities are installed with full production lines for synthesizing oligonucleotides and siRNA. Moreover, our recombinant proteins are fermented and purified using our patented purification systems.
After having a successful initial Public Offering, BIONEER corporation has launched a wholly-owned subsidiary, Bioneer Inc. The company has a wide range of expertise with a branch located in American, the heart of the San Francisco Bay Area, Alameda, with 1400 square feet of production and distribution. The company is distributing state of art solutions to the global community of life science researchers in academia, biotech and pharmaceutical companies.